Document ID: EPA-HQ-OPP-2023-0474-0014
Agency: epa
Document Type: Notice
Title: Endocrine Disruptor Screening Program: Near-Term Strategies for Implementation
Posted Date: 2023-12-14T05:00Z

[Federal Register Volume 88, Number 239 (Thursday, December 14, 2023)]
[Notices]
[Page 86644]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-27405]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2023-0474; FRL-11384-02-OCSPP]

Endocrine Disruptor Screening Program (EDSP); Near-Term 
Strategies for Implementation; Notice of Availability and Request for 
Comment; Extension of Comment Period

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: In the Federal Register of October 27, 2023, EPA announced the 
availability of and solicited comment on near-term strategies to help 
the Agency meet its obligations and commitments under the Federal Food, 
Drug, and Cosmetic Act (FFDCA), which requires, that EPA screen for and 
protect against endocrine disrupting effects in humans. This document 
extends the comment period, which was scheduled to end on December 26, 
2023, for 60 days.

DATES: The comment period for the document published in the Federal 
Register of October 27, 2023, at 88 FR 73841 (FRL-11384-01-OCSPP) is 
extended. Comments must be received on or before February 26, 2023.

ADDRESSES: Submit your comments, identified by docket identification 
(ID) number EPA-HQ-OPP-2023-0474, through the Federal eRulemaking 
Portal at https://www.regulations.gov. Follow the online instructions 
for submitting comments. Do not submit electronically any information 
you consider to be Confidential Business Information (CBI) or other 
information whose disclosure is restricted by statute. Additional 
instructions on commenting and visiting the docket, along with more 
information about dockets generally, is available at https://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Catherine Aubee, Endocrine Disruptor 
Screening Program (7505T), Office of Pesticide Programs, Environmental 
Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-
0001; main telephone number: (202) 566-1030; email address: 
[email protected].

SUPPLEMENTARY INFORMATION: 
    To give stakeholders additional time to review materials and 
prepare comments, EPA is hereby extending the comment period 
established in the Federal Register document of October 27, 2023, at 88 
FR 73841 (FRL-11884-01-OCSPP) for 60 days, from December 26, 2023, to 
February 26, 2023. More information on the action can be found in the 
Federal Register of October 27, 2023.
    To submit comments or access the docket, please follow the detailed 
instructions provided under ADDRESSES. If you have questions, consult 
the technical person listed under FOR FURTHER INFORMATION CONTACT.

(Authority: 7 U.S.C. 136 et seq. and 21 U.S.C. 346a)

    Dated: December 6, 2023.
Michal Freedhoff,
Assistant Administrator, Office of Chemical Safety and Pollution 
Prevention.
[FR Doc. 2023-27405 Filed 12-13-23; 8:45 am]
BILLING CODE 6560-50-P